BMS-536924
(Synonyms: 胰岛素样生长因子-1受体拮抗剂) 目录号 : GC17773
A dual inhibitor of IGF-1R and IR
Cas No.:468740-43-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
BMS-536924 is a novel inhibitor of IGF-1R with IC50 value of 100nM [1].
It has been found that BMS-536924 has cell toxicity in OVCAR-3 and OVCAR-4 cell lines. BMS-536924 inhibits cell proliferation partly via reducing phosphorylations of AKT and ribosomal protein S6, one of AKT’s downstream targets. [2].
BMS-536924 also induces apoptosis in vitro as indicated by the elevation of PARP-1 cleavage. It can induce DNA damage by the manner of increasing the phosphorylated histone H2AX as well as increasing the tail moment observed in the comet assay. It thus sensitizing cells to PARP inhibition [2].
References:
[1] Mark G. Saulnier, David B. Frennesson, Mark D. Wittman, Kurt Zimmermann, Upender Velaparthi, David R. Langley, Charles Struzynski, Xiaopeng Sang, Joan Carboni, Aixin Li, Ann Greer, Zheng Yang, Praveen Balimane, Marco Gottardis, Ricardo Attar and Dolatrai Vyas. 2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924. Bioorganic & Medicinal Chemistry Letters. 2008 (18):1702-1707.
[2] Marie-Claude Beauchamp, Ariane Knafo, Amber Yasmeen, Joan M. Carboni, Marco M. Gottardis, Michael N. Pollak, Walter H. Gotlieb. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecologic Oncology. 2009 Aug (115):193-198.
| Cas No. | 468740-43-4 | SDF | |
| 别名 | 胰岛素样生长因子-1受体拮抗剂 | ||
| 化学名 | (3E)-4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1,3-dihydrobenzimidazol-2-ylidene)pyridin-2-one | ||
| Canonical SMILES | CC1=CC(=CC2=C1NC(=C3C(=CC=NC3=O)NCC(C4=CC(=CC=C4)Cl)O)N2)N5CCOCC5 | ||
| 分子式 | C25H26ClN5O3 | 分子量 | 479.96 |
| 溶解度 | ≥ 24mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0835 mL | 10.4175 mL | 20.8351 mL |
| 5 mM | 0.4167 mL | 2.0835 mL | 4.167 mL |
| 10 mM | 0.2084 mL | 1.0418 mL | 2.0835 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。